UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware (State or Other Jurisdiction of |
| 0-19700 (Commission File Number) |
| 33-0266089 (I.R.S. Employer Identification No.) |
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 20, 2008, Alain D. Baron, M.D. resigned his position as Amylin’s Senior Vice President, Research, effective June 1, 2008. Dr. Baron served in various officer-level positions with Amylin since December 1999 and was a “named executive officer” in Amylin’s 2008 proxy statement. We anticipate entering into a consulting arrangement with Dr. Baron pursuant to which he will provide transitional services to the company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| AMYLIN PHARMACEUTICALS, INC. | |
|
|
| |
|
|
|
|
Dated: | May 22, 2008 | By: | /s/ Lloyd A. Rowland |
|
|
| Lloyd A. Rowland |
|
|
| Vice President, Governance and Compliance, and |
3